MAY 22·itemonline.com▲
Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants
Cosmos Health Inc. announced that 4,874,126 Series B warrants, representing approximately 38% of the company's total outstanding warrants, expired unexercised on May 19, 2026. This expiration eliminates a significant overhang with no dilution to existing shareholders and simplifies the company's capital structure. CEO Greg Siokas stated that this development is positive for shareholders and reflects the company's commitment to a cleaner, more shareholder-friendly capital structure.
MAY 14·Investing.com Canada→
Cosmos Health pursues €25M EIB financing for R&D program By Investing.com
Cosmos Health Inc. (NASDAQ:COSM) is seeking up to €25 million in financing from the European Investment Bank (EIB) for its €50 million R&D program, through its subsidiary Cana Laboratories. The potential funding, contingent on milestones, would support various therapeutic areas including weight management, oncology, multiple sclerosis, and allergic inflammation. This initiative comes as the company navigates significant debt and cash burn, despite its stock being considered undervalued by InvestingPro data.
